5269532026-01-012026-03-315269532026-03-315269532025-03-315269532025-04-012026-03-315269532026-01-012026-03-31in-capmkt:OtherExpenses1Member5269532026-01-012026-03-31in-capmkt:OtherExpenses2Member5269532025-04-012026-03-31in-capmkt:OtherExpenses1Member5269532025-04-012026-03-31in-capmkt:OtherExpenses2Member5269532026-03-31OtherNoncurrentFinancialAssetsDomain15269532026-03-31OtherNoncurrentFinancialAssetsDomain25269532026-03-31OtherNoncurrentAssetsDomain15269532026-03-31OtherCurrentFinancialAssetsDomain15269532026-03-31OtherCurrentAssetsDomain15269532026-03-31OtherNoncurrentLiabilitiesDomain15269532026-03-31OtherCurrentFinancialLiabilitiesDomain15269532026-03-31OtherCurrentFinancialLiabilitiesDomain25269532026-03-31OtherCurrentLiabilitiesDomain15269532026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15269532026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25269532025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15269532025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss25269532026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15269532025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15269532026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares526953VENUSREMNOTLISTEDINE411B01019VENUS REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-262026-05-15INRCroresQuarterlyFourth quarterSingle segmentPHARMACEUTICALS2026-05-2615:15:002026-05-2621:35:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated2594000000495000002643500000116280000047300000-145000002456000001000006760000051860000020275000006160000000616000000144800000-370000014110000004749000000000474900000-5490000042000000000001337000001035.5335.530035.5335.532025-04-012026-03-31AuditedConsolidated769600000012580000078218000003879800000107600000-11470000088680000040000025670000014637000006480300000134150000001341500000328900000-1520000031370000001027800000000010278000001000001027900000000013370000010663750000076.8976.890076.8976.89Selling , Manufacturing and Administrative expenses467600000Research & development expenses51000000Selling , Manufacturing and Administrative expenses1282000000Research & development expenses18170000012543000005136000000093980000000016382000000019930000018375000000398000004585000000129370000073800000010328000002512000004490000005300000207220000081800000504400000395210000000853710000013370000065038000006637500000663750000000281000001434000000110500000282000000012410000010108000001134900000418700000155360000020800000432000000016176000000018996000008537100000Right of use Assets121900000Other financial assets77400000Other non-current assets39800000Other financial assets5300000Other current assets504400000Lease Liability110500000Lease Liability13600000Other Financial Liability405100000Other current liabilities2080000059000000-18530000000-35500000000599200000000256700000032000000000021400000-594000000000005634000001904900000000342700000-4600000155760000000015256000000000037650000000000000000000000021400000065100000-18156000000000000001690000084000000590000000-31200000-289200000-34900000-324100000575200000251100000Items that will not be classified to Profit & Loss3800000Foreign Currency Translation Reserve-2000003600000Items that will not be classified to Profit & Loss1100000Foreign Currency Translation Reserve-8200000-710000000Items that will be classified to Profit & Loss-58500000-58500000Items that will be classified to Profit & Loss7200000720000000-54900000100000AuditedtrueJ K Jain Associatestrue2027-04-30